Plasmapheresis and paraproteinemia: Cryoprotein-induced diseases, monoclonal gammopathy, Waldenstrom's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis

Therapeutic Apheresis

Volumn 3, Issue 1, 1999, Pages 8-19

  Siami, Ghodrat A ^a   Siami, Flora S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amyloidosis; Cold agglutinin disease; Cryofibrinogenemia; Cryofiltration apheresis; Cryoglobulinemia; Hyperviscosity syndrome; Immunoadsorption; Light chain disease; Membrane fractionation; Monoclonal gammopathy; Multiple myeloma; Paraproteinemia; Plasmapheresis; Waldenstrom's macroglobulinemia

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; PENICILLAMINE; PREDNISONE; STANOZOLOL; STEROID; VINCRISTINE;

AMYLOIDOSIS; ARTICLE; CRYOGLOBULINEMIA; HUMAN; HYPERVISCOSITY SYNDROME; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PARAPROTEINEMIA; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT INDICATION; WALDENSTROEM MACROGLOBULINEMIA;

AMYLOIDOSIS; ANEMIA, HEMOLYTIC, AUTOIMMUNE; CRYOGLOBULINEMIA; HUMANS; MACROMOLECULAR SUBSTANCES; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMAPHERESIS; WALDENSTROM MACROGLOBULINEMIA;

EID: 0033007591     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.1999.00146.x     Document Type: Article

References (110)

1. Shumak KH, Rock GA. Therapeutic plasma exchange. New Engl J Med 1984;310(12):762-71.
2. Schneider KM. Plasmapheresis and immunoadsorption: Different techniques and their current role in medical therapy. Kidney Int 1998;53(Suppl. 64):S61-5.
3. Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal disease. J Am Soc Nephrol 1996;7(3):367-86.
4. Balint JP Jr. Immune modulation associated with extracorporeal immunoadsorption treatment utilizing protein A/silica columns. Artif Organs 1996;20(8):906-13.
5. Siami G, Stone WJ. Selective plasmapheresis using special secondary on-line filters in the therapy of immune disorders. Prog Clin Biol Res 1990;337:355-7.
6. Siami G, Hakim R. Therapy of homozygous type IIA familial hypercholesterolemia using special on-line plasma filter pheresis. Prog Clin Biol Res (Apheresis). 1990;337:209-12.
7. Siami GA, Siami FS. Cryofiltration apheresis in the United States. Ther Apheresis. 1998;2(3):228-35.
8. Pascual M, Mach-Pascual S, Schifferli JA. Paraproteins and complement depletion: Pathogenesis and clinical syndromes. Semin Hematol 1997;34(1,Suppl. 1):40-8.
9. Barlogie B, Alexanian R, Jagannath S. Plasma cell dyscrasias. JAMA. 1992;268:2946-51.
10. Malchesky PS, Clough JD. Cryoglobulins: Properties, prevalence in disease, and removal. Cleve Clin Q 1985;52:175-92.
11. Foerster J. Cryoglobulins and cryoglobulinemia. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's clinical hematology, 9th Ed. Vol. 2. Malvern: Lea and Febiger. 1993:2284-93.
12. Levo Y. Nature of cryoglobulinemia. Lancet. 1980;1(8263): 285-7.
13. Kawamura A, Osanai M, Yonekawa M. Immunomodulation in transplant patients by cryofiltration. Ther Apheresis. 1998;2(3):205-9.
14. Brouet JC, Clauvel JP, Dannon F, Kein M, Seligmann M. Biological and clinical significance of cryoglobulins: A report of 86 cases. Am J Med 1974;57:775-88.
15. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, Mazzoni A, Pasero G, Bombardieri S, Highfield P. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991;9(6):621-4.
16. Kerr GS, Rofail M, Lewis JH, Kumar P, Seeff LB. Prevalence of hepatitis C virus associated cryoglobulinemia at a veterans hospital. J Rheumatol 1997;24(11):2134-8.
17. Agnello V. Hepatitis C virus infection and type II cryoglobulinemia: An immunological perspective. Hepatology. 1997;26(6)1375-9.
18. Lunel F, Musset L. Hepatitis C infection and cryoglobulinemia. Trends Exp Clin Med 1998;8(1):95-103.
19. Siami GA, Siami FS, Ferguson P, Stone WJ, Zborowski M. Cryofiltration apheresis for treatment of cryoglobulinemia associated with hepatitis C. ASAIO J 1995;41(3):M315-8.
20. Agarwal A, Clements J, Sedmak DD, Imler D, Nahman NS, Orsinelli DA, Hebert LA. Subacute bacterial endocarditis masquerading as type III essential mixed cryoglobulinemia. J Am Soc Nephrol 1997;8(12):1971-6.
21. Sanders PW, Striker LJ. Mixed cryoglobulins, multiple myeloma, and light chain systemic disease. In: Jacobson HR, Striker GE, Klahr S, eds. Principles and practice of nephrology. St. Louis: Mosby Press. 1995:172-8.
22. Siami GA, Siami FS. Cryofiltration apheresis for treatment of cryoglobulin glomerulonephritis in renal transplant. Transplant Proc 1995;27(5):2583-4.
23. Sankarasubbaiyan S, Scott G, Holley JL. Cryofibrinogenemia: An addition to the differential diagnosis of calciphylaxis in end-stage renal disease. Am J Kidney Dis 1998;32(3): 494-8.
24. Hosoi K, Makino S, Yamano Y, Sasaki M, Takeuchi T, Sakane S, Ohsawa N. Cryofibrinogenemia with polyarthralgia, Raynaud's phenomenon, and acral ulcer in patient with Grave's disease treated with methimazole. Intern Med 1997;36(6):439-42.
25. Williamson AE, Cone LA, Huard GS. Spontaneous necrosis of skin associated with cryofibrinogenemia, cryoglobulinemia, and homocystinuria. Ann Vase Surg 1996;10(4):365-9.
26. Siami GA, Siami FS. Tandem cryofiltration apheresis and hemodialysis to treat patient with severe calciphylaxis, cryoglobulinemia, and end stage renal disease. ASAIO J (in press).
27. Foerster J. Autoimmune hemolytic anemia. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's clinical hematology, 9th Ed. Malvern: Lea & Febiger, 1993:1179-2208.
28. Park JV, Weiss CI. Cardiopulmonary bypass and myocardial protection: Management problems in cardiac surgical patients with cold autoimmune diseases. Anesth Analg 1988;67: 75-8.
29. Leach AB, Van Hasselt GL, Edwards JC. Cold agglutinins and deep hypothermia. Anesthesia. 1983;38(2):140-3.
30. Pruzanski W, Shumak KH. Biologic activity of cold reactive autoantibodies. New Engl J Med 1977;297(10):538-42.
31. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Hematol Oncol Clin N Am 1997;11(1):71-87.
32. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA, Pineda AA, O'Brien PC, Kyle RA. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New Engl J Med 1991;325(21): 1482-6.
33. Kissel JT, Mendell JR. Neuropathies associated with monoclonal gammopathies. Neuromusc Disorders. 1996;6(1):3-18.
34. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995;37(Suppl. 1):S32-42.
35. Dimopoulos MA, Alexanian R. Waldenström's macroglobulinemia. Blood. 1994;83(6):1452-9.
36. Waldenström JG, Raiend U. Plasmapheresis and cold sensitivity of immunoglobulin molecules. A study of hyperviscosity, cryoglobulinemia, euglobulinemia, and macroglobulinemia vera. Acta Med Scand 1984;216(5):449-66.
37. Keshgegian AA, Sevin P. Waldenström's macroglobulinemia associated with a mixed cryoglobulin: Report of a case with partial precipitation in vitro at 37 degrees C. Arch Pathol Lab Med 1979;103:270-3.
38. Macris NT, Capra JD, Frankel GJ, Ioachim HL, Satz H, Bruno MS. A lambda light chain cold agglutinin-cryomacroglobulin occurring in Waldenström's macroglobulinemia. Am J Med 1970;48(4):524-9.
39. Waldenström JG. Macroglobulinemia - a review. Haematologica. 1986;71:437-40.
40. Nobile-Orazio E, Marmiroli P, Baldini L, Spagnol G, Barbieri S, Moggio M, Polli N, Polli E, Scarlato G. Peripheral neuropathy in macroglobulinemia: Incidence and antigen-specificity of M proteins. Neurology. 1997;37(9):1506-14.
41. Waldenström J. Macroglobulinemia. Adv Metab Dis 1965;2: 115-58.
42. Reinhart WH, Lutolf O, Nydegger U, Mahler F, Straub PW. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: Influence on blood rheology and the microcirculation. J Lab Clin Med 1992;119(1):69-76.
43. Buxbaum J. Hyperviscosity syndrome in dysproteinemias. Am J Med Sci 1972;264(2):123-6.
44. Carter PW, Cohen HJ, Crawford J. Hyperviscosity syndrome in association with kappa light chain myeloma. Am J Med 1989;86:591-5.
45. Khan P, Rother MS, Keren DF, Foon KA. Light chain disease associated with hyperviscosity syndrome. Cancer. 1987;60(9):2267-8.
46. Kosmo MA, Gale RP. Plasma cell leukemia with IgA paraproteinemia and hyperviscosity. Am J Hematol 1988;28(2);113-5.
47. Avnstorp C, Nielsen H, Drachmann O, Hippe E. Plasmapheresis in hyperviscosity syndrome. Acta Med Scand 1985;217(1):133-7.
48. Bataille R, Harousseau JL. Multiple myeloma. New Engl J Med 1997;336(23):1657-64.
49. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. New Engl J Med 1994;330(7):484-9.
50. Kyle RA. Monoclonal proteins and renal disease. Ann Rev Med 1994;45:71-7.
51. Seiden MV, Anderson KC. Multiple Myeloma. Curr Opin Oncol 1994;6:41-9.
52. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. New Engl J Med 1998;338(22):1601-7.
53. Sanders PW. Myeloma kidney. Kidney 1993;25(4):1-7.
54. Lessard F, Bannon P, Lepage R, Joly JG. Light chain disease and massive proteinuria. Clin Chem 1985;31(3):475-7.
55. Hayes JS, Jankey N, Cuthbert AL, Das PM. Massive proteinuria in light chain disease. Arch Intern Med 1978;138(5): 785-6.
56. Bachrach HJ, Myers JB, Bartholomew WR. A unique case of kappa light-chain disease associated with cryoglobulinemia, pyroglobulinemia, and hyperviscosity syndrome. Am J Med 1989;86(5):596-602.
57. Dalal FR, Winsten S. Double light-chain disease: A case report. Clin Chem 1979;25(1):190-2.
58. Shustik C, Bergsagel DE, Pruzanski W. Kappa and lambda light chain disease: Survival rates and clinical manifestations. Blood 1976;48(1):41-51.
59. Fang LST. Light chain nephropathy. Kidney Int 1985;27: 582-92.
60. Ganeval D, Noël LH, Preud'homme JL, Droz D, Grünfeld JP. Editorial review. Light chain deposition disease: Its relation with AL-type amyloidosis. Kidney Int 1984;26:1-9.
61. Wood L, Jacobs P. The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels. J Clin Apheresis 1986;3(2):124-8.
62. Dau PC. Immunologic rebound. J Clin Apheresis 1995;10: 210-7.
63. Valbonesi M, Garelli S, Montani F, Cefis M, Rossi U. Management of immune-mediated and paraproteinemia diseases by membrane plasma separation and cascade filtration. Vox Sanguinis 1982;43(2):91-101.
64. Keller AJ, Chirnside A, Urbaniak SJ. Coagulation abnormalities produced by plasma exchange on the cell separator with special reference to fibrinogen and platelet levels. Br J Haematol 1979;42(4):593-603.
65. Ness PM, Pennington RM. Plasma fractionation in the United States. A review for clinicians. JAMA 1974;230(2): 247-50.
66. Samtleben WR, Anderson DH, Blumenstein M, Habersetzer R, Schmidt B, Gurland HJ. Membrane plasma exchange: Principles and application techniques. J Clin Apheresis 1984;2(2):163-9.
67. Siami G, Schapira M, Stone WJ. Correction of bleeding diathesis due to factor XI inhibitor by using special on-line plasma filter pheresis. Prog Clin Biol Res 1993;12:135-8.
68. Siami GA, Siami FS, Morrow JD, Stone WJ. Cryofiltration apheresis and plasma fractionation causing anaphylactoid reactions in patients receiving angiotensin converting enzyme inhibitors. Ther Apheresis 1997;1(4):325-9.
69. Hakim RM, Siami GA. Plasmapheresis. In: Daugirdas JT, Ing TS, eds. Dialysis handbook 2nd Ed. Boston: Little, Brown, and Company, 1994:218-41.
70. Malchesky PS, Kaplan A, Koo AP, Sakurada Y, Siami GA. Are selective macromolecule removal plasmapheresis system useful for auto-immune diseases or hyperlipidemia? ASAIO J 1993;39(4):868-72.
71. Siami GA, Wilkins WT, Stone WJ, Koo AP, Zborowski M. Clinical trials of cryoglobulin filter. ASAIO J 1994;40(3): M658-62.
72. Siami GA, Siami FS. Cryofiltration apheresis in the treatment of cryoprecipitate-induced diseases. Ther Apheresis 1997;1(1):58-2.
73. Caseril M, Capra F, Gabelli GB, Bassi A, Squarzoni S, Dagradi R, DeMaria E, Corrocher R. Cryoglobulinemia in hepatitis C virus, chronic active hepatitis effect of interferon alpha therapy. J Interfer Cytok Res 1996;16(8):585-8.
74. Tavoni A, Mosca M, Ferri C, Moriconi L, LaCivita L, Lombardini F, Bombardieri S. Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13(Suppl. 13):S191-5.
75. Houwert DA, Hene RJ, Struyvenberg A, Kater L. Effect of plasmapheresis (PP), corticosteroids, and cyclophosphamide in essential mixed polyclonal cryoglobulinemia associated with glomerulonephritis. Proc Eur Dial Transplant Assn 1980;17:650-4.
76. Delaney VB, Fraley DS, Segal DP, Bruns FJ. Plasmapheresis as sole therapy in a patient with essential mixed cryoglobulinemia. Am J Kidney Dis 1984;4(1)75-7.
77. Ferri C, Moriconi L, Gremignai G, Migliorini P, Paleologo G, Fosella PU, Bombardieri S. Treatment of renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986;43(4):246-53.
78. Berkman EM, Orlin JB. Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia. Transfusion 1980;20(2):171-8.
79. Valbonesi M, Montani F, Mosconi L, Florio G, Vecchi C. Plasmapheresis and cytotoxic drugs for mixed cryoglobulinemia. Haematologica 1984;17(3):341-51.
80. McLeod BC, Sassetti RJ. Plasmapheresis with return of cryoglobulin-depleted autologous plasma (cryoglobulinpheresis) in cryoglobulinemia. Blood 1980; 55:866.
81. L'Abbate A, Paciucci A, Bartolomeo F, Misefari V, Nobile F, Cerrai T, Maggiore Q. Selective removal of plasma cryoglobulins in cryoglobulinemia. Proc Eur Dial Transplant Assn 1977;14:486-94.
82. Yamashita M, Malchesky PS, Omokawa S, Horiuchi T, Zborowski M, Koo AP, Nosé Y. Limitation of plasmapheresis in cryoglobulinemia with high levels of cryoglobulins. Prog Clin Biol Res 1990;337:491-4.
83. Helfman T, Falanga V. Stanozolol as a novel therapeutic agent in dermatology. J Am Acad Dermatol 1995;33:254-8.
84. Kirsner RS, Eaglstein WH, Katz MH, Kerdel FA, Falanga V. Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. J Am Acad Dermatol 1993;28(1):71-4.
85. Copeman PW. Cryofibrinogenemia and skin ulcers: Treatment with plasmapheresis. Br J Dermatol 1979;101(Suppl 17):75-8.
86. Azuma E, Nishihara H, Hanada M, Nagai M, Hiratake S, Komada Y, Sakurai M. Recurrent cold hemagglutinin disease following allogenic bone marrow transplantation successfully treated with plasmapheresis, corticosteroid, and cyclophosphamide. Bone Marrow Transplant 1996;18(1):243-6.
87. Andrzejewski C, Gault E, Briggs M, Silberstein L. Benefit of a 37°C extracorporeal circuit in plasma exchange therapy for selected cases with cold agglutinin disease. J Clin Apheresis 1998;4:13-7.
88. Sherman WH, Olarte MR, McKiernan G, Sweeney K, Latov N, Hays AP. Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. J Neurol Neurosurg Psych 1984;47(8):813-9.
89. Huang YW, Vitetta ES. Immunotherapy of multiple myeloma. Stem Cells 1995;13:123-34.
90. Assessment of plasmapheresis. Report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996;47(3):840-3.
91. Oksenhendler E, Chevret S, Leger JM, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated polyneuropathy study group. J Neurol Neurosurg Psych 1995;59:243-7.
92. Siciliano G, Moriconi L, Gianni G, Richieri E, Vignocchi MG, Rossi B. Selective techniques of apheresis in polyneuropathy associated with monoclonal gammopathy of undetermined significance. Acta Neurol Scand 1994;89(2):117-22.
93. Weinstein R, Sato PT, Shelton K, Hartigan N, Ropper AH, Hays M, Cardillo K. Successful management of paraprotein-associated peripheral neuropathies by immunoadsorption of plasma with staphylococcal protein A. J Clin Apheresis 1993;8(2):72-7.
94. Heustis DW, Rifkin RM, Durie BG, Sibley WA, Irani M. An unexpected complication following immunoadsorption with staphylococcal protein A column. J Clin Apheresis 1992;7(2): 75-7.
95. Waterston JA, Brown MM, Ingram DA, Swash M. Cyclosporin A therapy in paraprotein-associated neuropathy. Muscle Nerve 1992;15(4):445-8.
96. Valbonesi M, Montani F, Guzzini F, Angelini G, Florio G. Efficacy of discontinuous flow centrifugation compared with cascade filtration in Waldenström's macroglobulinemia: A pilot study. Int J Artif Organs 1985;8(3):165-8.
97. Höffkes HG, Heemann UW, Teschendorf CH, Uppenkamp M, Philipp TH. Hyperviscosity syndrome: Efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenström's type. Clin Nephrol 1995;43(5):335-8.
98. Perry MC, Hoagland C. The hyperviscosity syndrome. JAMA 1976;236(4):392-3.
99. Jacobs P, Wood L, LeRoux I, Prior C, King HS. Waldenström's macroglobulinemia treated with sequential hemibody irradiation. J Clin Apheresis 1987;3:181-4.
100. Kes P, Pecanic Z, Getaldic B, Ratkovic-Gusic I. Treatment of hyperviscosity syndrome in the patients with plasma cell dyscrasias. Acta Med Croat 1996;50(4):173-7.
101. Buskard NA, Galton DA, Goldman JM, Kohner EM, Grindle CF, Newman DL, Twinn KW, Lowenthal RM. Plasma exchange in the long-term management of Waldenström's macroglobulinemia. Canadian Med Assn J 1977;117(2):135-7.
102. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange in acute renal failure due to multiple myeloma. Kidney Int 1988;33(6):1175-80.
103. Pasquali S, Cagnoli L, Rovinetti C, Rigotti A, Zucchelli P. Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma. Int J Artif Organs 1985;8(Suppl 2):27-30.
104. McLeod BC, Viernes AL, Sassetti RJ. Serum-free light chain analysis by crossed immunoelectrophoresis: Correlation with plasmapheresis in light chain disease nephropathy. Am J Hematol 1983;15(1):75-88.
105. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma: Plasmapheresis, hemodialysis and chemotherapy. Arch Intern Med 1990;150:863-9.
106. Berglund K, Thysell H, Keller C. Results, Principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year follow up of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993;20:2051-7.
107. Vernier I, Pourrat JP, Mignon-Conte MA, Hemery M, Dueymes JM, Conte JJ. Rapidly progressive glomerulonephritis associated with amyloidosis: Efficacy of plasma exchange. J Clin Apheresis 1987;3:226-9.
108. Nakazawa R, Azuma N, Suzuki M, Nakatani M, Nankou T, Furuyoshi S, Yasuda A, Takata S, Tani N, Kobayashi F. A new treatment for dialysis-related amyloidosis with beta 2-microglobulin column. Int J Artif Organs 1993;16(12): 823-9.
109. Gejyo F, Teramura T, Eli I, Arkawa M, Nakazawa R, Azuma N, Suzuki M, Furuyoshi S, Nankou T, Takata S. Long term clinical evaluation of an adsorbent column (BM-01) of direct hemoperfusion type for beta 2-microglobulin on the treatment of dialysis-related amyloidosis. Artif Organs. 1995;19(12):1222-6.
110. Swartz RD. Dialysis associated amyloidosis (DAA). Kidney. 1991;23(6):1-6.